Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).

18 Sep 2021

Study highlights the importance of deeply exploring the immune responses against cancer

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body's own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.

16 Sep 2021

Grouping EGFR mutations provides an accurate way to match lung cancer patients to the right drugs

Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provide an accurate framework to match patients with non-small cell lung cancer (NSCLC) to the right drugs.

16 Sep 2021

Lung cancer patients report high anxiety levels and experience treatment delays due to the pandemic

Patients coping with lung cancer and treated in one hospital in Mexico reported high levels of anxiety and saw their treatment delayed or due to the COVID-19 pandemic, according to a study presented today at the IASLC World Conference on Lung Cancer.

12 Sep 2021

Study shows how oncology practices changed after durvalumab approval for unresectable stage III NSCLC patients

A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.

12 Sep 2021

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases.

12 Sep 2021

Cellular program could turn T cells into effective cancer killers

Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.

9 Sep 2021

New insights could help unlock the mystery of how lung cancer arises in never smokers

A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body.

6 Sep 2021

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were recently published in JAMA Oncology.

25 Aug 2021

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

Immunotherapy agents that inhibit the molecules PD1, PD-L1 or CTLA-4 have become widely used in clinical practice to treat non-small cell lung cancer, or NSCLC.

20 Aug 2021

MD Anderson receives nearly $13 million from CPRIT to support research efforts

The University of Texas MD Anderson Cancer Center has been awarded $12.75 million from the Cancer Prevention and Research Institute of Texas to support basic, clinical, translational and prevention research efforts, including $3 million for a new project to build clinical trial network infrastructure across Texas.

19 Aug 2021

New assay using fresh uncultured lung tumor cells could guide personalized treatments

A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.

18 Aug 2021

Yale perspective highlights new breakthrough therapies to treat non-small cell lung cancer

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC).

12 Aug 2021

New approach could be a useful tool in the fight against cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

10 Aug 2021

Study may provide a new therapeutic target for treatment of LUAD patients

Aging-US published "A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma" which reported that RNA-seq transcriptome data of LUAD patients were obtained from The Cancer Genome Atlas database.

9 Aug 2021

Experimental drug combination extends survival in mice with lung cancer, study finds

A combination of experimental drugs increased the attack of immune cells on non-small cell lung cancer (NSCLC) to extend survival in mice, a new study found.

5 Aug 2021

MET amplification identified as a potentially actionable driver for non-small cell lung cancer

A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC).

20 Jul 2021

Non Small Cell Lung Cancer News and Research

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

Study highlights the importance of deeply exploring the immune responses against cancer

Grouping EGFR mutations provides an accurate way to match lung cancer patients to the right drugs

Lung cancer patients report high anxiety levels and experience treatment delays due to the pandemic

Study shows how oncology practices changed after durvalumab approval for unresectable stage III NSCLC patients

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Cellular program could turn T cells into effective cancer killers

New insights could help unlock the mystery of how lung cancer arises in never smokers

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

New prediction model can identify NSCLC patients who are not likely to respond to immunotherapy

MD Anderson receives nearly $13 million from CPRIT to support research efforts

New assay using fresh uncultured lung tumor cells could guide personalized treatments

Yale perspective highlights new breakthrough therapies to treat non-small cell lung cancer

New approach could be a useful tool in the fight against cancer drug resistance

Study may provide a new therapeutic target for treatment of LUAD patients

Experimental drug combination extends survival in mice with lung cancer, study finds

MET amplification identified as a potentially actionable driver for non-small cell lung cancer

Moffitt awarded $10.2 million grant to investigate lung cancer metabolism

Study highlights the impact of structural racism and residential segregation on lung cancer outcomes

PET/CT images can be used to measure biomarker levels, predict lung cancer outcomes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News